Former President and Chief Executive Officer and Current Chairman of the Board of Directors (5) · ARS Pharmaceuticals, Inc. (SPRY)

Peter Thompson

FY2020 is the first fiscal year CompBrief holds for Peter Thompson as a named executive officer of ARS Pharmaceuticals; the record below is that year, complete. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2020

$551,641

Salary $0Stock awards $0

4th of 4 named executive officers at ARS Pharmaceuticals by FY2020 total.

4 named officers on file for ARS Pharmaceuticals, FY2020

Peter Thompson’s pay file — $29

  • 1 fiscal year of pay, line by line
  • 1 equity grant, each cited to its filing
  • SPRY’s disclosed peer group of 18 companies

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how ARS Pharmaceuticals’s whole pay program stands against its peers

  • ARS Pharmaceuticals’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on SPRY→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed April 22, 2021 (DEF 14A). Insider transactions since that proxy, current to 2026-11-21.

Free

Get Peter Thompson’s full pay file as a PDF — free

More than this page: up to 10 years of Peter’s pay history, a side-by-side peer comparison, and a one-page board summary — the whole file, yours now and by email.

Peter Thompson compensation by year

ARS Pharmaceuticals Summary Compensation Table · the one fiscal year held
In US dollars, as ARS Pharmaceuticals reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2020
Salary$0
Bonus$0
Stock awards$0
Option awards$546,519
Non-equity incentive$0
Pension and deferred compensation$0
All other$5,122
Total$551,641

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: ARS Pharmaceuticals, Inc. DEF 14A filed April 22, 2021, accession 0001193125-21-126673, and prior-year filings. Open the filing on EDGAR.

How this page was built: the ARS Pharmaceuticals, Inc. filed document, accession 0001193125-21-126673. Every figure is read from that document and cited to the page and table it appears in. Filed April 22, 2021.

Equity holdings

unvested awards at FY2020 year-end
TypeUnvested unitsValue at year-endExercise price
Option38,270—$21.00

Per the Outstanding Equity Awards at Fiscal Year-End table in ARS Pharmaceuticals, Inc.'s FY2020 proxy; value at the fiscal year-end close, as the company printed it.

Insider transactions since the last proxy

8 Form 4 lines since the FY2020 proxy (filed April 22, 2021)
current to 2026-11-21 · updated nightly
DateTransactionPlanSharesPriceHeld after
2026-06-24Grant or award derivative—30,000$0.0030,000
2025-06-25Grant or award derivative—30,000$0.0030,000
2024-08-26Sale—83,695$13.000
2024-08-23Sale—69,500$13.0383,695
2024-08-22Sale—391,482$12.94153,195
2024-08-21Sale—13,300$14.61544,677
2024-08-21Sale—394,400$13.52557,977
2024-06-20Grant or award derivative—40,000$0.0040,000

The 8 most recent of 8 lines, each as reported on the Form 4. "10b5-1" marks a trade the filing reports under a pre-arranged trading plan. View every Form 4 filing on EDGAR →

ARS Pharmaceuticals’s named executive officers, FY2020

as the company reported each
Named executive officerRoleFY2020 total
Laura ShawverChief Executive Officer$13,819,725
Valerie OdegardPresident and Chief Scientific Officer$7,154,203
Jonathan PiazzaChief Financial Officer$6,209,273
Peter Thompson · this pageFormer President and Chief Executive Officer and Current Chairman of the Board of Directors (5)$551,641

Board service

ARS Pharmaceuticals board · FY2022–FY2025
Director compensation in US dollars, as ARS Pharmaceuticals reports it. Most recent year first; a dash means the company reported no figure in that column.
Fiscal yearCash feesStock awardsOption awardsOtherTotal
FY2025$55,000—$367,959$0$422,959
FY2024$47,500—$232,932$0$280,432
FY2023$43,750—$198,800$0$242,550
FY2022$65,836—$59,492$0$125,328

Each year as the company reported it in ARS Pharmaceuticals's director compensation table. Totals are the company's own disclosed totals.

How this board is paid

Company policy: ARS Pharmaceuticals pays directors a $50,000 cash retainer. As stated in ARS Pharmaceuticals's FY2025 proxy.

Committees

Compensation

The full ARS Pharmaceuticals compensation record

free company brief

This page is one person within ARS Pharmaceuticals's record. The company brief lists every named executive, each linking to their own page.

Peer companies

named in the ARS Pharmaceuticals proxy · each links to its own free brief

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are ARS Pharmaceuticals's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Peter Thompson's compensation dossier · One-time report. No refunds.